Literature DB >> 16613234

Metastatic chest wall tumor suspected to be of lung origin by immunoreactivity for cytokeratin 7 and 20.

Shuji Haraguchi1, Masafumi Hioki, Mina Takushima, Kunio Yanagimoto, Kiyoshi Koizumi, Kazuo Shimizu.   

Abstract

We report a rare case of unknown primary carcinoma. A 36-year-old man was admitted to the hospital because of a chest wall tumor. Serum carcinoembryonic antigen level was 160 ng/ml. The resected chest wall tumor was pathologically diagnosed as metastatic adenocarcinoma, showing positive immunoreactivity for cytokeratin 7 and negative immunoreactivity for cytokeratin 20, suggesting lung origin. Serum carcinoembryonic antigen level returned to normal limits. Twenty-one months later, a chest X-ray showed a nodular lesion in the left upper lobe and serum carcinoembryonic antigen level increased to 12.3 ng/ml. Left upper lobectomy was performed 23 months after chest wall resection. The resected tumor was pathologically diagnosed as primary lung adenocarcinoma, showing the same immunoreactivity as in the chest wall tumor. The combination of immunohistochemistry for cytokeratin 7 and 20 appeared to be a useful tool in determining the site of origin and helpful for premortem diagnosis of the origin of unknown primary carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613234     DOI: 10.1007/BF02744878

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  9 in total

1.  Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma.

Authors:  K R Hess; M C Abbruzzese; R Lenzi; M N Raber; J L Abbruzzese
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

2.  Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer.

Authors:  B P Rubin; A T Skarin; E Pisick; M Rizk; R Salgia
Journal:  Eur J Cancer Prev       Date:  2001-02       Impact factor: 2.497

3.  Pneumothorax manifesting primary lung cancer.

Authors:  Daisuke Okada; Kiyoshi Koizumi; Shuji Haraguchi; Masashi Kawamoto; Iwao Mikami; Shigeo Tanaka
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-03

4.  An autopsy case of cytokeratin 7-positive minute adenocarcinoma of the lung with systemic metastases.

Authors:  Y Ise; H Yanagawa; T Hirose; K Tani; S Yano; Y Suzuki; E Takeuchi; K Maniwa; E Shimizu; F Ogushi; T Sano; S Sone
Journal:  Intern Med       Date:  1998-09       Impact factor: 1.271

5.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.

Authors:  R Moll; A Löwe; J Laufer; W W Franke
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

Review 6.  Evaluation of the patient with carcinoma of unknown origin metastatic to bone.

Authors:  Bruce T Rougraff
Journal:  Clin Orthop Relat Res       Date:  2003-10       Impact factor: 4.176

7.  Metastatic malignant disease of unknown origin.

Authors:  A O Gaber; P Rice; C Eaton; J J Pietrafitta; E Spatz; P J Deckers
Journal:  Am J Surg       Date:  1983-04       Impact factor: 2.565

8.  Metastatic bone disease from occult carcinoma: a profile.

Authors:  M Nottebaert; G U Exner; A R von Hochstetter; A Schreiber
Journal:  Int Orthop       Date:  1989       Impact factor: 3.075

9.  Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas.

Authors:  T S Loy; R D Calaluce
Journal:  Am J Clin Pathol       Date:  1994-12       Impact factor: 2.493

  9 in total
  1 in total

1.  Review of chest wall tumors: a diagnostic, therapeutic, and reconstructive challenge.

Authors:  Elizabeth A David; M Blair Marshall
Journal:  Semin Plast Surg       Date:  2011-02       Impact factor: 2.314

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.